Skip to main content
. 2022 Dec;17(12):1754–1762. doi: 10.2215/CJN.08900722

Figure 3.

Figure 3.

(A and B) Eventfree survival and (C and D) treatment benefits with combination treatment versus placebo treatment for doubling of serum creatinine/kidney failure. (A) Kaplan–Meier estimated curves for patients starting at age 50 years. (B) Kaplan–Meier estimated curves for patients starting at age 55 years. (C) Treatment benefits on eventfree survival. (D) Difference in eventfree survival between two treatments.